Eris Lifesciences (BOM:540596) Change In Payables And Accrued Expense : ₹0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Eris Lifesciences Change In Payables And Accrued Expense?

Eris Lifesciences's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was ₹0 Mil. It means Eris Lifesciences's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Mar. 2024 .

Eris Lifesciences's Change In Payables And Accrued Expense for the fiscal year that ended in Mar. 2024 was ₹0 Mil. It means Eris Lifesciences's Accounts Payable & Accrued Expense stayed the same from Mar. 2023 to Mar. 2024 .

Eris Lifesciences Change In Payables And Accrued Expense Historical Data

The historical data trend for Eris Lifesciences's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eris Lifesciences Change In Payables And Accrued Expense Chart

Eris Lifesciences Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Eris Lifesciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Eris Lifesciences Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

Eris Lifesciences Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Eris Lifesciences's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Eris Lifesciences (BOM:540596) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eris Lifesciences Ltd (BOM:540596) » Definitions » Change In Payables And Accrued Expense

Traded in Other Exchanges

ERIS:India

Address

Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054

Website

https://www.eris.co.in

Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast.

Eris Lifesciences (BOM:540596) Headlines

No Headlines